Galectin-1 Pulls the Strings on VEGFR2.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24529367.
- Also identified by DOI 10.1016/j.cell.2014.01.059.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.
Medical subject headings
- Angiogenesis Inhibitors
- Neoplasms
- Neovascularization, Pathologic
- Vascular Endothelial Growth Factors